Prostate cancer perspectives after chaarted: Optimizing treatment sequence

Critical Reviews in Oncology/Hematology

Volumn 107, Issue , 2016, Pages 119-127

  Estévez, Sergio Vázquez ^a   Herranz, Urbano Anido ^b   Calvo, Ovidio Fernández ^c   Afonso Afonso, Francisco Javier ^d   Couto, Lucía Santomé ^e   Quintela, Martín Lázaro ^f   Mateos, Luis León ^g   Maciá Escalante, Sonia ^h  

^a HOSPITAL UNIVERSITARIO LUCUS AUGUSTI   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^c Servicio de Medicina de Familia y Comunitaria   (Spain)

^d Universidad de La Coruña   (Spain)

^e HOSPITAL POVISA   (Spain)

^f UNIVERSITY HOSPITAL COMPLEX OF VIGO   (Spain)

^g Medical Oncology Department   (Spain)

^h Pivotal CRO   (Spain)

Author keywords

Alpha emitters; CHAARTED; Docetaxel; Hormonotherapy; Immunotherapy; Prostate cancer

Indexed keywords

ABIRATERONE ACETATE; ANTIANDROGEN; CABAZITAXEL; CABOZANTINIB; CANCER VACCINE; CUSTIRSEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DOCETAXEL; ENZALUTAMIDE; IPILIMUMAB; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; RADIOISOTOPE; RADIUM; RADIUM 223; SIPULEUCEL T; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ALGORITHM; ANDROGEN DEPRIVATION THERAPY; BACKACHE; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; DRUG EFFICACY; DRUG SAFETY; EDEMA; FATIGUE; FLUID RETENTION; HEART DISEASE; HORMONE SENSITIVITY; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPOKALEMIA; LIVER TOXICITY; METASTASIS POTENTIAL; NAUSEA; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PROSTATE CANCER; RADIOISOTOPE THERAPY; REVIEW; SIDE EFFECT; SURVIVAL TIME; TREATMENT RESPONSE; HORMONE SUBSTITUTION; IMMUNOTHERAPY; MALE; ORCHIECTOMY; PROSTATE TUMOR;

ANTINEOPLASTIC AGENTS; HORMONE REPLACEMENT THERAPY; HUMANS; IMMUNOTHERAPY; MALE; ORCHIECTOMY; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS;

EID: 85017317845     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2016.08.007     Document Type: Review

References (50)

1. Anido Herranz, U., Fernández Calvo, O., Afonso Afonso, F.J., Rodríguez Martínez de Llano, S., Lázaro Quintela, M., et al. Radium-223 dichloride: a new paradigm in the treatment of prostate cancer. Expert Rev. Anticancer Ther. 15:March (3) (2015), 339–348.
2. A Study of Alpharadin® With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC). 2010. Available from: http://clinicaltrials.gov/show/NCT01106352.
3. https://clinicaltrials.gov/ct2/show/NCT01578655.
4. Atkins, H.L., Overview of nuclides for bone palliation. Appl. Radiat. Isot. 49 (1998), 277–283.
5. Beer, T.M., Armstrong, A.J., Rathkopf, D.E., Loriot, Y., Sternberg, C.N., Higano, C.S., et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N. Engl. J. Med. 371:July (5) (2014), 424–433.
6. Bouchet, L.G., Bolch, W.E., Goddu, W.M., et al. Considerations in the selection of radiopharmaceuticals for palliation of bone pain from metastatic osseous lesions. J. Nucl. Med. 41 (2000), 682–687.
7. Caffo, O., Pappagallo, G., Russo, L.M., Veccia, A., Galligioni, E., Docetaxel rechallenge in patients with castration-resistant prostate cancer – a review. Eur. Oncol. Haematol. 8:1 (2012), 36–41, 10.17925/EOH.2012.08.01.36.
8. Chi, Kim N., Hotte, Sebastien J., Yu, Evan Y., et al. Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. JCO(September), 2010, 4247–4254.
9. Chi, K.N., Higano, C., Reeves, J., et al. A randomized phase 3 study comparing first-line docetaxel/prednisone (DP) to DP plus custirsen in men with metastatic castration-resistant prostate. Ann. Oncol. 25:Suppl. 4 (2014), iv255–iv279.
10. European Association of Urology. Prostate cancer guidelines, 2016.
11. Ferlay, J., Steliarova-Foucher, E., Lortet-Tieulent Rosso, S., Coebergh, J.W.W., Cancer incidence and mortality patterns in Europe:estimates for 40 countries in 2012. Eur. J. Cancer 49:April (6) (2013), 1374–1403.
12. Fizazi, K., Scher, H.I., Molina, A., Logothetis, C.J., Chi, K.N., Jones, R.J., et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 13:October (10) (2012), 983–992.
13. Gillesen, S., Omlin, A., Attard, G., deBono, J.S., Efstathiou, E., Fizazi, K., et al. Management of patients with advanced prostate cancer: recommendations of the St. Gallen advanced prostate cancer consensus conference (APCCC) 2015. Ann. Oncol. 26:November (11) (2015), 2354–2355, 10.1093/annonc/mdv360.
14. Gravis, G., Boher, J.M., Joly, F., Soulié, M., Albiges, L., et al. Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU 15. Trial Eur. Urol., 2015, 21 (Epub ahead of print).
15. Gravis, G., Boher, J.M., Joly, F., Oudard, S., Albiges, L., et al. Androgen deprivation therapy (ADT) plus docetaxel (D) versus ADT alone for hormone-naïve metastatic prostate cancer (PCa): Long-term analysis of the GETUG-AFU 15 phase III trial. J. Clin. Oncol., 33(Suppl. 7), 2015 (abstr 140).
16. Harland, S., Staffurth, J., Molina, A., Hao, Y., Gagnon, D.D., Sternberg, C.N., et al. Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy. Eur. J. Cancer 49:November (17) (2013), 3648–3657.
17. Heidenreich, A., Bastian, P.J., Bellmunt, J., Bolla, M., Joniau, S., van der Kwast, T., et al. EUA guidelines on prostate cancer Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur. Urol. 65:February (2) (2014), 467–479.
18. Higano, C.S., Corman, J.M., Smith, D.C., et al. Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer 113:5 (2008), 975–984.
19. James, N.J., Syders, M.R., Clarke, N.W., Mason, M., Dearmaley, D., et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet Oncol., 2015 (Published Online December 21, 2015) http://dx.doi.org/10.1016/S0140-6736(15)01037-5.
20. Kantoff, P.W., Higano, C.S., Shore, N.D., et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363:5 (2010), 411–422.
21. Kantoff, P.W., Schuetz, T.J., Blumenstein, B.A., et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J. Clin. Oncol. 28:7 (2010), 1099–1105.
22. Krishnamurthy, G.T., Krishnamurthy, S., Radionuclides for metastatic bone pain palliation: a need for rational re-evaluation in the new millennium. J. Nucl. Med. 41 (2000), 688–691.
23. Kwon, E.D., Drake, C.G., Scher, H.I., Fizazi, K., Bossi, A., et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 15:June (7) (2014), 700–712.
24. Loblaw, D.A., Virgo, K.S., Nam, R., et al. Initial hormonal management of androgen-sensitive metastatic, recurrent or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J. Clin. Oncol. 25 (2007), 1596–1605.
25. Madan, R.A., Arlen, P.M., Mohebtash, M., et al. Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer. Expert Opin. Investig. Drugs 18:7 (2009), 1001–1011.
26. Maxon, H.R., Schroder, L.E., Hertzberg, V.S., Thomas, S.R., Englaro, E.E., et al. Rhenium-196(Sn) HEDP for treatment of painful osseous metastases: results of a double-blind crossover comparison with placebo. J. Nucl. Med. 32 (1991), 1877–1881.
27. Morris, M.J., Autio, K.A., Basch, E.M., et al. Monitoring the clinical outcomes in advanced prostate cancer: what imaging modalities and other markers are reliable?. Semin. Oncol. 40:June (3) (2013), 375–392.
28. NCCN Guidelines Version 1.2015 Prostate cancer.
29. NCCN Clinical Practice Guidelines in Oncology. Version 3.2016.
30. Nilsson, S., Franzen, L., Parker, C., Tyrrell, C., Blom, R., et al. Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastases. Clin. Genitourin. Cancer 11 (2013), 20–26.
31. Okegawa, T., Itaya, N., Hara, H., et al. Circulating tumor cells as a biomarker predictive of sensitivity to docetaxel chemotherapy in patients with castration-resistant prostate cancer. Anticancer Res. 1:November (2014), 6705–6710.
32. Parker, C., Nilsson, S., Heinrich, D., Helle, S.I., O'Sullivan, J.M., Fosså, S.D., et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N. Engl. J. Med. 369:July (3) (2013), 213–223.
33. Parker, C., Gillesen, S., Heidenreich, A., Horwich, A., on behalf of the ESMO Guidelines Committee, Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 24:6 (2013), vi106–vi114.
34. Petrylak, D.P., Tangen, C.M., Hussain, M.H., et al. Docetaxel and Estramustine compared with mitoxantrone and prednisolone for advanced refractory prostate cancer. N. Engl. J. Med. 351 (2004), 1515–1527.
35. Robinson, R.G., Preston, D.F., Schiefelbein, M., Baxter, K.G., Strontium-89 therapy for the palliation of pain due to osseous metastases. JAMA 274 (1995), 420–424.
36. Ryan, C.J., Smith, M.R., de Bono, J.S., Molina, A., Logothetis, C.J., de Souza, P., et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N. Engl. J. Med. 368:January (2) (2013), 138–148.
37. Sartor, O., Coleman, R., Nilsson, S., Heinrich, D., Helle, S.I., et al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol. 15:June (7) (2014), 738–746.
38. Sartor, O., Oudard, S., Sengelov, L., Daugaard, G., Saas, F., et al. Cabazitaxel vs docetaxel in chemotherapy-naive (CN) patients with metastatic castration-resistant prostate cancer (mCRPC): a three-arm phase III study (FIRSTANA). J. Clin. Oncol., 34(suppl), 2016 (abstr 5006).
39. Scher, H.I., Fizazi, K., Saad, F., Taplin, M.E., Sternberg, C.N., Miller, K., et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 367:13 (2012), 1187–1197.
40. Serafini, A.N., Houston, S.J., Resche, I., et al. Palliation of pain associated with metastatic bone cancer using Samarium-153 lex-idronam: a double-blind placebo-controlled clinical trial. J. Clin. Oncol. 16 (1998), 1574–1581.
41. Small, E., Higano, C., Tchekmedyian, T., et al. Randomized phase II study comparing 4 monthly doses of ipilimumab (MDX-010) as a single agent or in combination with a single dose of docetaxel in patients with hormone-refractory prostate cancer. J. Clin. Oncol., 24(18S), 2006, 4609.
42. Small, E., Higano, C., Tchekmedyian, N., Sartor, O., Stein, B., et al. Randomized phase II study comparing 4 monthly doses of ipilimumab (MDX-010) as a single agent or in combination with a single dose of docetaxel in patients with hormone-refractory prostate cancer. J. Clin. Oncol., 24, 2006 (abstr 4609).
43. Small, E.J., Tchekmedyian, N.S., Rini, B.I., et al. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin. Cancer Res. 13:6 (2007), 1810–1815.
44. Small, E., Demkow, T., Gerritsen, W.R., et al. A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer (CRPC). Genitourinary Cancers Symposium, 2009, 7.
45. Smith, D.C., Smith, M.R., Sweeney, C., et al. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J. Clin. Oncol. 31 (2013), 412–419.
46. Smith, M.R., de Bono, J.S., Sternberg, C., Le Moulec, S., Oudard, S., et al. Final analysis of COMET-1: Cabozantinib (Cabo) versus prednisone (Pred) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E). J. Clin. Oncol., 33(Suppl. 7), 2015 (abstr 139).
47. Srivastava, S.C., Atkins, H.L., Krishnamurthy, G.T., et al. Treatment of metastatic bone pain with tin-117 m Stannic diethylenetriaminepentaacetic acid: a phase I/II clinical study. Clin. Cancer Res. 4 (1998), 61–68.
48. Sweeney, C.J., Chen, Y.H., Carducci, M., Liu, G., Jarrard, D.F., et al. Chemohormonal therapy in metastatic hormone-Sensitive prostate cancer. N. Engl. J. Med. 373:August (8) (2015), 737–746.
49. Vale, C.L., Burdett, S., Rydzewska, L., Albiges, L., Clarke, N., et al. Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. Lancet Oncol., 2015 (Published Online December 21, 2015) http://dx.doi.org/10.1016.
50. Vogelzang, N., Helle, S., Johannessen, D., O'sullivan, J., Garcia-Vargas, J., O'Bryan-Tear, C., et al. Efficacy and safety of radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases who did or did not receive prior docetaxel (D) in the phase III ALSYMPCA trial. J. Clin. Oncol., 31(Suppl), 2016, 5068 (abstract).